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Background: Shenling Baizhu San (SBS) is a well-known and classical Chinese medicine formula. It has been used
for treatment of gastrointestinal disorders for about nine hundred years. Recent reports showed that it was effective
in curing colitis and ameliorating the major manifestations of postoperational colorectal cancer (CRC). This study was to
evaluate the effects of SBS on azoxymethane (AOM) and dextran sodium sulfate (DSS) induced colitis associated CRC
(caCRC) and to analyze the underlying mechanism of SBS in preventing CRC.
Methods: The colon tissue of mice in different group was determined by immunohistochemistry and western blot.
TGF-β1 in serum was measured by ELISA. Myeloid-derived suppressor cells (MDSCs) were identified by flow cytometry
and immunohistochemistry.
Results: The formed neoplasms phenotypically resembled human caCRC with upregulated β-catenin, p53 and
proliferating cell nuclear antigen (PCNA). SBS treatment reduced the death rate of mice and decreased the incidence
and multiplicity of colonic neoplasms. SBS decreased the number of MDSCs and the level of transforming growth
factor β1 (TGF-β1). SBS alleviated epithelial mesenchymal transition (EMT) through downregulating N-cadherin (N-cad),
Vimentin, Fibronectin, Snail, and upregulating E-cadherin (E-cad). It reduced the activation of Wnt5a and EMT induced
by TGF-β1.
Conclusions: SBS reduced the death rate through decreasing the incidence and multiplicity of colonic tumors. SBS
lowered MDSCs infiltration and inhibited TGF-β1 induced EMT to exert its anti-caCRC effects.
Keywords: Shenling Baizhu San, Colitis associated colorectal cancer, Epithelial mesenchymal transition, Myeloid-derived
suppressor cells, Snail, Transforming growth factor β1Background
Colorectal cancer (CRC) is the third most common can-
cer in men and the second in women worldwide [1].
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unless otherwise stated.estimated number of new cancer cases and deaths of
CRC in the United States are 142,820 (9%) and 50,830
(9%) in 2013 [2]. Although great progress have been
made in the diagnosis and treatment, surgery remains
the only curative option and still 40%-50% of colorectal
cancer patients died of the disease within five years of
diagnosis [3]. The increasing toxicity profile and ac-
quired chemotherapy resistance urge us to look for ef-
fective adjuvant therapies as well as improved treatment
options for CRC.
Shenling Baizhu San (SBS) is a well-known and canon-
ical Chinese medicine formula first described in “Thes is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Pharmacy” in Song-dynasty. The principle of the pre-
scription is to replenish Qi and invigorate Spleen, re-
solve dampness and relieve diarrhea according to
traditional Chinese medicine (TCM) theory. SBS is ef-
fective in ameliorating the major manifestations of post
operational CRC, such as exhaustion and fatigue, dull
and yellow complexion, anorexia, nausea, diarrhea and
abdominal distension [4]. It improves Karnofsky per-
formance scale (KPS) score and increases CD4+, CD8+
and natural killer (NK) cells in post operational CRC pa-
tients with Spleen-deficiency [5]. SBS decreases the
tumor weight and increases serum interleukin 2 (IL-2),
interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α)
in mice with xenografted hepatocellular cancers [6]. SBS
also inhibits Lewis lung cancer growth and decreases IL-10,
increases IFN-γ, NK cells and the ratio of CD4/CD8 [7].
There are evidences that SBS is effective in inhibiting or
delaying the growth of CRC, hepatocellular cancer and lung
cancers [5-7]. SBS is also effective in curing chronic colitis
[8,9]. However, little was known if SBS can prevent colitis
associated CRC (caCRC), as it is one of the three highest
risk groups for developing CRC: ulcerative colitis (UC),
familial adenomatous polyposis, and hereditary nonpoly-
posis colon cancer syndrome [10].
The epithelial-mesenchymal transition (EMT) is a
process in which epithelial cells trans-differentiate and ac-
quire an invasive mesenchymal phenotype. Activated nu-
clear factor-κB (NF-κB), signal transducer and activator of
transcription 3 (STAT3), Ras-mitogen-activated protein
kinase (MAPK), β-catenin and their controlled cytokines
such as IL-1β, IL-6, IL-10, transforming growth factor-β
(TGF-β) and TNF-α play pivotal roles in the formation of
EMT [11]. On the other hand, the constitutive activation
of MAPK, STAT3, β-catenin, and various other signaling
pathways trigger the secretion of immunosuppressive mol-
ecules, e.g., TGF-β, IL-10, vascular endothelial growth fac-
tor (VEGF), and chemokine (C-C motif) ligand 2, etc. [12].
These molecules induce immunosuppressive immune cells,
such as regulatory T cells (Tregs) and myeloid-derived sup-
pressor cells (MDSCs) recruitment and accumulation in
the tumor site that facilitate the development and metasta-
sis of CRC [12]. MDSCs are a heterogeneous group of
myeloid progenitor cells and immature myeloid cells that
inhibit lymphocyte function by inducing regulatory T cells
(Tregs); producing TGF-β and IL-10 [13]. Recently, it was
reported that MDSCs suppressed antitumour immune re-
sponses and promoted cancer cell proliferation and metas-
tasis by inducing epithelial to mesenchymal transition [14].
In our study, we found that SBS could inhibit the incidence
of azoxymethane (AOM) and dextran sodium sulfate
(DSS) induced caCRC. Furthermore, the underlying mech-
anism related to EMT and immunosuppression was also
investigated.Methods
SBS preparation
SBS, comprised of ten commonly used herbs: Radix Et
Rhizoma Ginseng, (root of Panax ginseng C.A. Mey., Jilin,
China), Poria (sclerotium of Poria cocos., Sichuan, China),
Rhizoma Atractylodis Macrocephalae (root of Atractylodes
macrocephala Koidz., Anhui, China), Semen Lablab
Album (seed of Dolichos lablab L., Hebei, China), Rhizoma
Dioscoreae (root of Dioscorea opposita Thunb., Henan,
China), Radix Et Rhizoma Glycyrrhizae (root of Glycyrrhiza
uralensis Fisch., Inner Mongolia, China), Plumula Nelumbinis
(spire and radicle of seed of Nelumbo nucifera Gaertn.,
Fujian, China), Fructus Amomi (seed of Zingiberaceae,
Amomum villosum Lour., Yangchun, China), Semen Coicis
(nut of Coix lachrhryma-jobi L.var.mayuen (Roman) Stapf.,
Fujian, China), Radix Platycodonis (root of Platycodon
grandiflorum(Jacq.)A.DC., Anhui, China). The raw herbs
for SBS were purchased from the affiliated Nan Fang
Hospital of Southern Medical University. The herbs
were identified as genuine regional drug by Prof Chen
Xingxing, an expert of Chinese medicine identification,
Southern Medical University. A voucher specimen was
deposited in the Herbarium of school of traditional
Chinese medicine. These were mixed in the ratio of
15:15:15:12:15:9:9:6:9:6 (dry weight). Aqueous extracts of
SBS were extracted at 80°C by stirring it for 1 h using 10
volumes of distilled water (v/m). Then, we centrifuged the
extract at 1,500 × g at room temperature. To obtain the
semisolid SBS solution, the supernatant was collected and
subjected to condensation under reduced pressure at 70°C.
The quality of SBS was controlled by HPLC analysis
(Additional file 1: Figure S1, Table S1, Figure S2). SBS
was suspended again in 0.9% saline at a final concentration
of 2 g/mL. The solution was stored in aliquots at −20°C.Animals and experimental procedure
All procedures involving laboratory animals were conducted
in accordance with the guidelines of the Instituted Animal
Care and Use Committee of Southern Medical University.
All protocols were submitted and validated by Animal Care
Ethics Committee of Southern Medical University (No.
2012–055). Male C57BL/6 J mice (specific pathogen-
free) were obtained from the Laboratory Animal Center
of Southern Medical University. The animals were main-
tained under controlled conditions (22°C, 12-h/12-h
dark/light cycle) in a conventional animal colony. The
mice were between 6 and 8 weeks old at the beginning
of the experiments, and weighed 15–20 g. There were 65
mice used in the study, 15 mice in normal control (con-
trol) group, 30 in AOM/DSS (model) group and 20 in
AOM/DSS & SBS (SBS) group. At the end of the study,
there were 15 surviving mice in control group, 9 in model
group and 12 in SBS group, respectively.
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DSS were shown in Figure 1A [15,16]. At week 2, C57BL/6 J
mice were injected with AOM (10 mg · kg−1, i.p.). 1 week
later, 3% DSS (International Lab, Chicago, IL, USA) was
added to the drinking water for 7 days followed by 14 days
of tap water for recovery. This cycle was repeated twice.
SBS (7.28 g/kg) or equivalent normal saline was adminis-
tered by gavage using a tube twice a day. The mice were
killed by cervical dislocation at week 16 and the colons
(from the ileocecal junction to the anal verge) were re-
moved. After measuring the length and weight, the colons
were cut open longitudinally along the main axis, washed
with phosphate-buffered saline (pH 7.4, 4°C) and then
macroscopically inspected. The number, size and location
of pre-neoplastic and neoplastic lesions (dysplasia and car-
cinoma) in the colons were recorded based on gross exam-
ination. The sizes of dysplasia were measured by an ocular
micrometer. After gross examination, the colons were cutFigure 1 Effects of SBS on the general well being of mice treated with AOM/
model. (B) Effect of SBS on body weight of mice. (C) Effect of SBS on the surv
Data are presented as mean ± SD vs. control and model.into pieces at about 1 cm intervals. One third of colon
samples were fixed in 10% buffered formalin (pH 7.4); one
third was kept in 10 volumes of RNAlater Solution
(Ambion, Life technologies, Carlsbad, CA, USA) and the
remaining one third was flash-frozen in liquid nitrogen
and stored at −80°C for further immunohistochemistry,
PCR and protein analysis, respectively.Reagents
Ginsenoside Rc (GRc) and Atractylenolide-1 (AT1) were
purchased from CHENGDU MUST BIO-TECHNOLOGY
Co., Ltd. Dimethyl sulfoxide (DMSO) and thiazolyl blue
tetrazolium bromide (MTT) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). RPMI 1640, FBS and antibi-
otics were purchased from Invitrogen (Gibco, Grand
Island,NY, USA). Recombinant Human TGF-β1 was pur-
chased from Whiga (PeproTech Inc, USA).DSS. (A) Experimental protocol for colitis-associated colon carcinogenesis
ival ratio of mice. SBS enhanced animal survival ratio (P = 0.04, vs. Model).
Table 1 Colon and spleen assessment in mice
Colon Spleen
Group Weight (g) Length (cm) W/L ratio Weight (g) SW/BW ratio
Model (n = 9) 0.52 ± 0.094△ 5.70 ± 0.444△ 0.09 ± 0.018△ 0.35 ± 0.039△ 0.018 ± 0.0021△
Control (n = 15) 0.23 ± 0.020 9.08 ± 0.521 0.02 ± 0.002 0.07 ± 0.006 0.003 ± 0.0002
SBS (n = 12) 0.35 ± 0.064* 7.77 ± 0.548* 0.05 ± 0.009* 0.17 ± 0.031* 0.007 ± 0.0015*
*P < 0.01 vs. model.
△P < 0.01 vs. control.
Lin et al. BMC Complementary and Alternative Medicine  (2015) 15:126 Page 4 of 15Cell viability assays
MTT assay was used to analyze the effects of GRc , AT1
and SBS on cell viability in two kinds of colorectal adeno-
carcinoma cell lines SW480,HCT116. Cells were routinely
maintained in RPMI 1640, supplemented with 10% FBS
and antibiotics (50 U/ml of penicillin and 50 μg/ml strepto-
mycin) at 37°C in a humidified atmosphere containing 5%Figure 2 SBS reduced the incidence and multiplicity of colonic neoplasms. (A)
size. SBS significantly delayed tumor growth and reduced neoplasms size. Dat
(C) Most of colorectal neoplasms were histologically consistent with tubular a
on haematoxylin and eosin (H&E) staining as described. (Ca) Normal colon; (C
scale bar = 100 μm.CO2. Cell number was measured on a standard microscope
by manual counting of cells using a grid with an area of
0.25 mm2. 1 × 104 Cells were seeded on 96-well plates in a
100 μl volume. The MTT assay was performed by addition
of MTT to a final concentration of 0.5 mg/ml of medium.
After 4 h, the medium was removed, and 150 μl of DMSO
was added to each well. After 10 min of shaking at roomMicroscopic view of colon in mice. (B) Effect of SBS on colonic neoplasms
a were presented as mean ± SD. *P < 0.01 vs. model, #P < 0.05 vs. model.
denoma or adenocarcinoma. Histological studies were carried out based
b) tubular adenoma, (Cc) adenocarcinoma. 40× for all,
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new 96-well plate, and absorbance at 562 nm was read with
a background subtraction at 660 nm.Preparation of MDSCs
Spleen and tumors were collected and cut into small pieces
before incubation for 15 min at 37°C with the followingFigure 3 Effects of SBS on oncogenic protein expression. (A) Immunohisto
tumor tissues or normal colonic tissues. 200× for all, scale bar = 100 μm. SB
respectively, but not COX-2. (B) Western blot analysis of β-catenin, COX-2, p53
was reduced in SBS group compared with model group, except COX-2. Semienzymes dissolved in HBSS: collagenase Type I (0.05 mg/ml),
collagenase Type IV (0.05 mg/ml), hyaluronidase
(0.025 mg/ml), and DNase I (0.01 mg/ml) and soybean
trypsin inhibitor (0.2 trypsin inhibitor unit/ml). The
digested cells were harvested, and the RBCs were lysed by
using hypotonic buffer (0.155 M NH4Cl, 0.1 mM EDTA,
10 mM KHCO3) for 1 min. CD11b+ cells were isolated by
using anti-CD11b magnetic immunobeads according tochemical staining of β-catenin, COX-2, p53 and PCNA expression in
S significantly decreased the expression of β-catenin, p53 and PCNA,
, PCNA expression in colonic tissues. The expression of these proteins
quantitive analysis of these proteins is showed in Tables 2 and 3.
Table 2 Semiquantitive analysis of Immunohistochemical
staining
Control (n = 15) Model (n = 9) SBS (n = 12)
β-catenin 0.07 ± 0.06 5.74 ± 2.87▲ 1.07 ± 0.91#
COX-2 1.23 ± 0.89 1.87 ± 1.25 2.07 ± 1.46
p53 0.97 ± 1.24 6.71 ± 3.81△ 2.67 ± 2.58#
PCNA 0.97 ± 1.13 6.00 ± 3.01△ 2.91 ± 1.84#
E-cadherin 3.37 ± 1.82 0.06 ± 0.04▲ 4.76 ± 2.18#
N-cadherin 0.92 ± 0.75 7.09 ± 2.90△ 3.34 ± 2.47#
Fibronectin 1.06 ± 1.08 9.07 ± 3.87△ 4.88 ± 3.10#
Vimentin 1.03 ± 1.07 6.49 ± 3.32△ 3.10 ± 2.35#
CD11b+Ly6g+ 0.03 ± 0.04 2.82 ± 0.95△ 1.00 ± 0.64#
#P < 0.05 vs. model.
△P < 0.01 vs. control; ▲P < 0.05 vs. control.
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Berdish-Gladbach, Germany).Cytokine measurement by enzyme-linked immunosorbent
assay
The level of TGF-β1 in serum was measured using mice
TGF-β1 Elisa kit (Novatein Biosciences, Woburn, MA,
USA) according to its protocol.Flow cytometric analysis of MDSCs
To analyze CD11b+ cell surface antigen expression, allo-
phycocyanin (APC)-conjugated anti-CD11b (M1/70,
PharMingen) and PE-conjugated anti-Ly6g (Gr-1; RB6-8C5,
PharMingen) were used. All antibodies were used at
10 μg/ml. The cells were incubated with the antibodies for
30 min at 4°C and washed with PBS. The samples wereTable 3 Semiquantitive analysis of Western blot
Control (n = 15) Model (n = 9) SBS (n = 12)
β-catenin 0.11 ± 0.03 0.36 ± 0.08△ 0.08 ± 0.02*
COX-2 0.52 ± 0.05 0.31 ± 0.07△ 0.27 ± 0.03
p53 0.15 ± 0.06 0.69 ± 0.08△ 0.36 ± 0.06*
PCNA 0.09 ± 0.01 0.57 ± 0.04△ 0.32 ± 0.04*
E-cadherin 0.81 ± 0.06 0.28 ± 0.03△ 0.45 ± 0.09#
N-cadherin 0.16 ± 0.05 0.71 ± 0.12△ 0.48 ± 0.07#
Snail 0.13 ± 0.05 0.56 ± 0.11△ 0.38 ± 0.09#
Vimentin 0.15 ± 0.06 0.73 ± 0.04△ 0.42 ± 0.26*
Frizzled 0.08 ± 0.02 0.17 ± 0.07▲ 0.07 ± 0.02#
Axin 0.52 ± 0.09 0.08 ± 0.04△ 0.32 ± 0.05*
Dvl2 0.66 ± 0.05 0.17 ± 0.04△ 0.44 ± 0.10*
P-Gsk-3β 0.32 ± 0.05 0.15 ± 0.08▲ 0.55 ± 0.07*
Gsk-3β 0.34 ± 0.06 0.36 ± 0.11 0.35 ± 0.11
Wnt5a 0.18 ± 0.03 0.66 ± 0.06△ 0.42 ± 0.05*
*P < 0.01 vs. model; #P < 0.05 vs. model.
△P < 0.01 vs. control; ▲P < 0.05 vs. control.fixed with 1% paraformaldehyde/PBS and analyzed by
using a FACSCalibur flow cytometer and CellQuest soft-
ware (Becton Dickinson Japan, Tokyo).
Histopathological assessment
For histopathological examination, formalin fixed, paraffin-
embedded colon tissues were cut into serial sections (5 μm)
and stained with haematoxylin and eosin (H&E) staining.
Histological alterations such as dysplasia and carcinoma
were verified. Assessment of dysplasia and adenocarcinoma
was based on the criteria set forth in the Mouse Models of
Intestinal Cancers consensus report: location, presence/
absence of prolapse/herniation, size (in mm), dysplasia
grade, invasion level, presence of desmoplasia, and presence
of irregular architecture [10]. Carcinoma was defined as
high-grade dysplasia of colonic mucosa which invaded be-
yond the muscularis mucosa and into the submucosa [15].
Immunohistochemistry
Paraffin-embedded colon sections were dewaxed, rehy-
drated, and pre-treated with hydrogen peroxidase in PBS
buffer. Heat-induced antigen retrieval was performed.
After blocking with the appropriate antisera in blocking
buffer, sections were incubated with anti-Proliferating cell
nuclear antigen (PCNA) (Thermo scientific, clone PC10,
1:300 dilution), anti-β-catenin (Cell Signaling Technology,
CST, clone 6B3, 1:100 dilution), anti-p53 (Leica-microsys-
tems, clone CM5, 1:100 dilution), or anti-COX-2 (Thermo
scientific, 1:100 dilution), anti-E-cadherin (CST, clone
24E10, 1:200 dilution), anti-N-cadherin (Millipore, clone
EPR1792Y, 1:50 dilution), anti-Fibronectin (Epitomics,
clone F14, 1:200 dilution) and anti-Vimentin (CST, clone
D21H3, 1:50 dilution). After incubation with HRP-
conjugated secondary antibody and tyramide amplification
followed by streptavidin-HRP, positive signals were visual-
ized by DAB kit , and counter-stained with hematoxylin.
Double staining of CD11b+Ly6g+ cells was carried out
using Polink RRt DouSP kit (ZSGB-BIO ORIGENE,
China). CD11b (abcam, clone EPR1344, 1:100 dilution),
Ly6g (abcam, clone RB6-8C5, 1:20 dilution). Five randomly
selected fields from each section were examined at a
magnification of 400× and analyzed using NIS-Elements.
The positive content was calculated using the following
formula: positive content (PC) =mean optical density ×
positive area.
Western blot analysis
Aliquots of Colonic tissues were homogenized in liquid
nitrogen, dissolved in lysis buffer [7 mol/L urea, 2 mol/L
thiourea, 4% (w/v) CHAPS, 20 mmol/L Tris, 65 mmol/L
DTT, 0.2% pharmalyte 3/10 ampholyte] supplemented
with 8 μl of protease inhibitor cocktail (The protease
inhibitor cocktail include AEBSF hydrochloride 500 μM,
Aprotinin 150nM, E-64 protease inhibitor 1 μM, EDTA
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chem, San Diego, CA, USA). The samples were then centri-
fuged at 15,000 × g for 30 min at 4°C. Protein concentrations
were determined with modified Bradford assay. The pro-
tein lysates were loaded onto 10% SDS-PAGE for separ-
ation and electrotransferred to PVDF membranes and
blocked in 5% non-fat milk in Tris-buffered saline (TBST,
100 mM NaCl, 50 mM Tris, 0.1% Tween-20, pH 7.5).
Membranes were incubated overnight with primary anti-
bodies [anti-PCNA (CST, clone PC10, 1:1000 dilution),
anti-β-catenin (CST, clone 6B3, 1:1000 dilution), anti-p53
(Leica-microsystems, clone CM5, 1:1000 dilution), or anti-
COX-2 (CST, clone D5H5 1:1000 dilution), anti-E-cadherin
(CST, clone 24E10; 1:1000 dilution), anti-N-cadherin
(Millipore, clone EPR1792Y, 1:5000 dilution), anti-
Vimentin (CST, clone D21H3, 1:1000 dilution), anti-Figure 4 Effects of SBS, AT1 and GRc on colorectal cancer cells in vitro. (A) E
to 0–16 mg/mL SBS and incubated for 12 and 24 h. Cell viability was measure
viability compared to 0-only. *P < 0.01 vs. 0 mg/mL; #P < 0.05 vs. 0 mg/mL. (B
to 0–120 μM/L AT1 and incubated for 24 and 48 h. Cell viability was measure
viability compared to 0-only. *P < 0.01 vs. 0 μM/L; #P < 0.05 vs. 0 μM/L. (C) Effe
0–100 μM/L GRc and incubated for 24 and 48 h. Cell viability was measured by
compared to 0-only. *P < 0.01 vs. 0 μM/L; #P < 0.05 vs. 0 μM/L.Snail (CST, clone C15D3, 1:1000 dilution), anti-Frizzled
(Santa Cruz, clone F-13, 1:1000 dilution), anti-
Dishevelled-2 (CST, clone 30D2; 1:1000 dilution), anti-
Glycogen synthase kinase 3β (GSK-3β) (CST, clone 27C10,
1:1000 dilution), anti-phosphorylated GSK-3β (Serine 9)
(CST, clone Ser9, 1:1000 dilution), anti-Wnt5a (CST, clone
C27E8, 1:1000 dilution)] at 4°C. This was followed by in-
cubation with horseradish peroxidase (HRP) conjugated
secondary antibodies. The results were visualized with
chemiluminescence (ECL, GE Healthcare Bio-science,
Uppsata, Sweden). The images were captured and docu-
mented with a CCD system (imagestation 2000MM,
Kodak, Rochester, NY, USA). The quantitative analysis of
these images was performed using Molecular Imaging Soft-
ware Version 4.0, provided by Kodak 2000 MM System. The
optical density was normalized against that of β-actin [16].ffects of SBS on proliferation of SW480 and HCT116. Cells were exposed
d by MTT methods and values were expressed as percentage of the cell
) Effects of AT1 on proliferation of SW480 and HCT116. Cells were exposed
d by MTT methods and values were expressed as percentage of the cell
cts of GRc on proliferation of SW480 and HCT116. Cells were exposed to
MTT methods and values were expressed as percentage of the cell viability
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Each experiment was repeated at least three times. Data
were presented as mean ± SD. All data were analyzed
using the SPSS statistical package (version 13.0, SPSS Inc,
Chicago, IL, USA). Survival rate was analyzed with
Kaplan-Meier survival analysis. Data between two groupsFigure 5 Effects of SBS on MDSCs and serum TGF-β1. (A) Immunohistochem
200 × for all, scale bar = 100 μm. SBS decreased the expression of MDSCs. Sem
MDSCs in spleen and tumor. SBS decreased the number of MDSCs versus mo
semiquantitive analysis of Flow cytometry analysis of MDSCs. Serum contents o
vs. model, #P< 0.05 vs. model; △P< 0.01 vs. control, ▲P< 0.0 5 vs. control.were compared with 2-independent samples tests. Mean
values of data from more than 3 groups were compared
with one-way analysis of variance (ANOVA) and multi-
comparison was performed. The correlation analysis was
determined by Spearman’s correlation coefficient. A value
of P < 0.05 was considered as statistically significant.ical double staining of MDSCs in tumor tissues or normal colonic tissues.
iquantitive analysis is showed in Table 2. (B) Flow cytometry analysis of
del group. (C) Enzyme-linked immunosorbent assay of serum TGF-β1 and
f TGF-β1 was reduced by SBS. Data are presented as mean ± SD. *P< 0.01
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Effects of SBS on the general well being of mice treated
with AOM/DSS
AOM/DSS was used to induce caCRC and effects of SBS on
caCRC were evaluated (Figure 1A). Body weight loss and
bloody stools were observed in mice exposed to DSSFigure 6 Effects of SBS on EMT markers and Wnt pathway molecules. (A) Imm
in tumor tissues or normal colonic tissues. 200 × for all, scale bar = 100 μm. S
Vimentin expression. (B) Western blot of E-cadherin, N-cadherin, Vimentin, Sn
group. The expression of E-cadherin was up-regulated and the expression of
(C) Western blot analysis of Wnt pathway molecules. SBS increased the express
of EMT markers is showed in Tables 2 and 3.(Figure 1B). These symptoms were relieved during the re-
covery periods. The mean colon weights were increased and
the mean colon length were decreased significantly in mice
receiving AOM/DSS (Table 1) as compared to the control
group. The significant increase in colon weight to colon
length ratio was a result of apparent mucosal thickening.unohistochemical staining of E-cadherin, N-cadherin, Fibronectin, Vimentin
BS increased the E-cad expression, decreased N-cadherin, Fibronectin,
ail in colonic tissues. E-cadherin was significantly deficient in model
N-cadherin, Fibronectin, Vimentin were downregulated by SBS treatment.
ion of Dvl2, Axin, and p-GSK-3β, decreased Wnt5a. Semiquantitive analysis
Figure 7 Effects of SBS of oncogenic protein and EMT marker expression
on colorectal cancer cells, HCT116, SW480. (A) Western blot of β-catenin,
COX-2, p53 and PCNA expression on SW480 and HCT116 exposed to 0,
10, 12 mg/mL SBS. The expression levels of these proteins were reduced
in a dose-dependent manner. Semiquantitive analysis of these proteins is
showed in Tables 4 and 5. (B) Western blot of E-cad, N-cad, Vimentin
and Snail expression on SW480 and HCT116 exposed to 0, 10, 12 mg/mL
SBS. The expression levels of N-cad, Vimentin and Snail were reduced in
a dose-dependent manner, while E-cad was increased in a dose-dependent
manner. Semiquantitive analysis of these proteins is showed in Tables 4
and 5.
Table 4 Semiquantitive analysis of Western blot on
HCT116
0 (n = 3) 10 (n = 3) 12 (n = 3)
β-catenin 0.34 ± 0.03 0.15 ± 0.02* 0.03 ± 0.02*
COX-2 0.57 ± 0.05 0.53 ± 0.04 0.55 ± 0.03
p53 0.74 ± 0.06 0.48 ± 0.08* 0.25 ± 0.04*
PCNA 0.87 ± 0.04 0.66 ± 0.04* 0.61 ± 0.04*
E-cadherin 0.08 ± 0.01 0.33 ± 0.02* 0.34 ± 0.05*
N-cadherin 0.84 ± 0.06 0.62 ± 0.03* 0.52 ± 0.03*
Snail 0.84 ± 0.04 0.74 ± 0.02* 0.63 ± 0.05*
Vimentin 0.43 ± 0.05 0.31 ± 0.02# 0.31 ± 0.05#
Axin 0.01 ± 0.01 0.17 ± 0.04* 0.33 ± 0.04*
Dvl2 0.10 ± 0.04 0.14 ± 0.04 0.22 ± 0.04*
p-Gsk-3β 0.22 ± 0.05 0.42 ± 0.05* 0.52 ± 0.04*
Gsk-3β 0.74 ± 0.04 0.84 ± 0.03# 0.89 ± 0.04*
*P < 0.01 vs. 0 mg/mL; #P < 0.05 vs.0 mg/mL.
Table 5 Semiquantitive analysis of Western blot on
SW480
0 (n = 3) 10 (n = 3) 12 (n = 3)
β-catenin 0.38 ± 0.05 0.23 ± 0.04* 0.23 ± 0.03*
COX-2 0.50 ± 0.03 0.49 ± 0.07 0.55 ± 0.03
p53 0.70 ± 0.03 0.17 ± 0.04* 0.14 ± 0.04*
PCNA 0.83 ± 0.05 0.71 ± 0.07# 0.59 ± 0.04*
E-cadherin 0.01 ± 0.01 0.23 ± 0.04* 0.27 ± 0.06*
N-cadherin 0.53 ± 0.05 0.36 ± 0.04* 0.32 ± 0.06*
Snail 0.63 ± 0.05 0.42 ± 0.04* 0.42 ± 0.06*
Vimentin 0.58 ± 0.05 0.29 ± 0.08* 0.28 ± 0.03*
Axin 0.08 ± 0.01 0.09 ± 0.03 0.23 ± 0.05*
Dvl2 0.09 ± 0.04 0.11 ± 0.09 0.25 ± 0.04#
P-Gsk-3β 0.34 ± 0.05 0.46 ± 0.05# 0.63 ± 0.05*
Gsk-3β 0.74 ± 0.05 0.85 ± 0.04# 0.93 ± 0.04*
*P < 0.01 vs. 0 mg/mL; #P < 0.05 vs. 0 mg/mL.
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was pre-screened. The medium dose SBS (7.28 g/kg) was
the selected optimal dose with satisfactory efficacy for it
retarded the development of neoplasms significantly
(Additional file 2). The body weight fluctuation and muco-
sal thickening were substantially alleviated in mice receiv-
ing SBS treatment. Based on Kaplan-Meier survival curves
(Figure 1C), SBS treatment significantly increased the
survival rate of mice.
SBS reduced the incidence and multiplicity of colonic
neoplasms
AOM/DSS treatment resulted in 100% incidence of co-
lonic neoplasms. Most of the neoplasms were distributed
in the middle and distal colon (Figure 2A). SBS treat-
ment decreased the total multiplicity of colorectal neo-
plasms by 34.8% (P < 0.01). It is noteworthy that SBSsignificantly retarded the development of large neoplasms
(diameter >3 mm) by 60% (Figure 2B). Histological assess-
ment showed that most of the lesions in the colon were
tubular adenoma or adenocarcinoma according to criteria
of Mouse Models of Intestinal Cancers (Figure 2C).
To determine whether AOM/DSS induced caCRC
phenotypically resembles human caCRC, we assessed the
expression of neoplastic markers by immunohistochemis-
try. Similar to human caCRC, PCNA and β-catenin ex-
pression were increased in dysplastic and neoplastic
lesions (Figure 3A-B, Tables 2 and 3). Intense nuclear
staining for p53 (CM5 clone: detects both mutant and
wild-type forms) was detected in the neoplastic epithelium
and in nondysplastic crypts; an observation that is highly
suggestive of p53 mutations [10]. However, no high-level
Figure 8 Effects of SBS of Wnt pathway molecules on colorectal cancer
cells, HCT116 and SW480. (A) Western blot of Axin, Dvl2, p-Gsk-3β and
Gsk-3β expression on SW480 and HCT116 exposed to 0, 10, 12 mg/mL
SBS. Semiquantitive analysis of these proteins is showed in Tables 4 and 5.
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(Figure 3A-B, Tables 2 and 3).
SBS and AT1 reduced CRC cell viability
To further analyze the anti-tumor effects of SBS, cell
proliferation was evaluated in SW480 and HCT116 cells
treated with SBS and its two ingredients, AT1 and GRc.
SBS significantly decreased cell viability in a time- and
dose-dependent manner from 10 mg/mL to 16 mg/mL.
The viabilities of SW480 and HCT116 cells decreased to
53.8714% and 41.2625% after 24 h of treatment with
12 mg/mL SBS (Figure 4A). AT1, but not GRc, signifi-
cantly decreased cell viability in a time-and dose-
dependent manner. The viabilities of SW480 and HCT116
cells decreased to 44.9733% and 55.032% after 48 h of
treatment with 100 μM/L AT1 (Figure 4B).
SBS decreased MDSCs infiltration and reduced TGF-β1
Immunohistochemical double staining of CD11b+Ly6g+ cell
showed that the number of MDSCs was increased in model
group and decreased by SBS treatment (Figure 5A, Table 2).
This result was corfirmed by Flow cytometric analysis of
CD11b+Ly6g+ cell in spleen and tumor (Figure 5B-Ca-b).
TGF-β1, the major effector molecule of MDSCs, was in-
creased in model group and decreased by SBS treatment
(Figure 5Cc).
The effects of SBS on expression of EMT markers and Wnt
pathway molecules
TGF-β1 induces epithelial mesenchymal transition and
increases the stablization of β-catenin [17], the effects of
SBS on EMT and Wnt pathway were tested. A constitu-
tive expression of E-cadherin was found in epithelials of
the control group. In accordance with the occurrence of
EMT, E-cadherin expression was downregulated in
model group. SBS increased the E-cad expression moder-
ately (Figure 6A, Table 2). Furthermore, the other three
EMT markers, N-cad, Fibronectin and Vimentin were
strongly expressed in model group and were decreased by
SBS significantly (Figure 6A, Table 2). Western blot ana-
lysis confirmed increased expression of E-cad, and
decrease of N-cad and Vimentin. We also found that up-
regulation of Snail, a transcription factor that plays a
pivotal role in the formation of EMT, was decreased by
SBS (Figure 6B, Table 3).
Wnt5a was increased in model group and was decreased
by SBS while Wnt3a was not detected. SBS increased the
expression of Axin, Disheveled 2 (Dvl2). The phosphoryl-
ation of glycogen synthase kinase-3β (GSK-3β) at serine 9
was elevated in control group and reduced in model
group, SBS increased the phosphorylation of GSK-3β
moderately (Figure 6C, Table 3).
The in vivo results were further confirmed in CRC cell
lines. SBS decreased the expression levels of PCNA, β-catenin, p53 in a dose-dependent manner (Figure 7A,
Tables 4 and 5). SBS increased the E-cad expression
significantly, and decreased the expression of N-cad,
Vimentin and Snail in a dose-dependent manner (Figure 7B,
Tables 4 and 5). It increased the expression of Axin, Dvl2
and glycogen synthase kinase-3β (GSK-3β) in a dose-
dependent manner. The phosphorylation of glycogen
synthase kinase-3β (GSK-3β) at serine 9 was increased
in SBS group (Figure 8, Tables 4 and 5). Furthermore, the
Spearman’s correlation analysis showed that β-catenin
negatively correlated with p-GSK-3β (r = −0.818, P = 0.007).
SBS inhibited the upregulation of Wnt5a and β-catenin
induced by TGF-β1
To further elucidate the mechanism of SBS in TGF-β1
mediated Wnt pathway, the expression of β-catenin and
Wnt5a and phoshorylation of GSK-3β was examined.
TGF-β1 induced the expression of β-catenin and Wnt5a
and dephosphotylated GSK-3β at ser 9. SBS reduced the
expression of β-catenin and Wnt5a and increased the
phosphorylation of GSK-3β in both HCT116 and SW480
cells. It also reversed the downregulation of E-cad in cells
treated with TGF-β1 (Figure 9, Table 6).
Discussion
Azoxymethane (AOM) is a procarcinogen causes forma-
tion of O6-methylguanine upon metallic activation [18].
Repeated DSS administration causes chronic inflamma-
tion which mimics IBD. Three cycles of DSS in combin-
ation with a single injection of AOM resulted in 100%
incidence of colonic neoplasms in mice in our research.
The neoplasms occured mainly in the middle to distal
colon which was the corresponding segment of DSS in-
duced colitis [18]. Therefore, inflammation provides a
suitable ground for the formation of neoplasms in the
Lin et al. BMC Complementary and Alternative Medicine  (2015) 15:126 Page 12 of 15colon. Upon DSS administration, mass death in model
group was delayed and alleviated by SBS treatment.
The AOM/DSS induced neoplasm resembles human
caCRC in several aspects of its molecular pathogenesis,
specifically in both increased PCNA and β-catenin expres-
sion and nuclear translocation of the latter. Wild-type p53
is a rapidly degraded protein with a short half-life and a
low cellular level [19]. The accumulation of p53 in model
group and translocation to nuclear are also features of
caCRC for early loss of function of p53 [10]. SBS not only
increased the survival rate of mice, reduced the incidence
and multiplicity of colonic neoplasms, but also downregu-
lated the expression of caCRC markers, such as PCNA, β-Figure 9 SBS inhibited the upregulation of Wnt5a and β-catenin induced by
TGF-β1 induced the expression of β-catenin and Wnt5a and dephosphotylate
and increased the phosphorylation of GSK-3β in both HCT116 and SW480 cel
of SBS on caCRC.catenin and p53, suggested that SBS was highly efficacious
in ameliorating caCRC [16].
TGF-β1 was upregulated in our caCRC mice. It in-
duces a dose dependent increasing of β-Catenin protein
levels and a up to 5 fold transcriptional activity of β-
Catenin responsive promoters [20]. AOM is known to
induce mutations in exon 3 of Ctnnb, which causes con-
stitutive activation of the Wnt pathway by stabilizing β-
catenin [18]. So, various mutations around the GSK-3β
phosphorylation sites on β-catenin combined with the
upregulation of TGF-β might be causative to β-catenin
accumulation in our study [18,20]. The phosphorylation
at Ser9 of GSK-3β might be result of TGF-β activation.TGF-β1. (A)Western blot analysis of Wnt pathway molecules. 10 ng/mL
d GSK-3β at ser 9. SBS reduced the expression of β-catenin and Wnt5a
ls. Semiquantitive analysis is showed in Table 6. (B) A diagram of effects
Table 6 Semiquantitive analysis of Western blot on
SW480 and HCT116
T (n = 3) C (n = 3) T + S (n = 3) S (n = 3)
E-cadherin-H 0.16 ± 0.07 0.12 ± 0.04 0.58 ± 0.13* 1.54 ± 0.17
β-catenin-H 1.57 ± 0.05 1.36 ± 0.10 1.03 ± 0.10* 0.92 ± 0.08
p-Gsk-3β-H 0.84 ± 0.07 1.46 ± 0.12 1.24 ± 0.09* 1.65 ± 0.09
Gsk-3β-H 1.64 ± 0.08 1.48 ± 0.06 1.50 ± 0.03# 1.47 ± 0.06
Wnt5a-H 1.61 ± 0.08 1.21 ± 0.04 0.90 ± 0.13* 0.52 ± 0.10
E-cadherin-S 0.11 ± 0.03 0.16 ± 0.05 0.71 ± 0.16* 1.25 ± 0.17
β-catenin-S 1.63 ± 0.09 1.48 ± 0.04 1.25 ± 0.09* 1.15 ± 0.06
p-Gsk-3β-S 0.57 ± 0.16 1.06 ± 0.14 1.38 ± 0.07* 1.74 ± 0.11
Gsk-3β-S 1.57 ± 0.05 1.55 ± 0.04 1.53 ± 0.05 1.54 ± 0.08
Wnt5a-S 1.86 ± 0.13 1.59 ± 0.06 1.26 ± 0.09* 1.03 ± 0.09
T: 10 ng/mL TGF-β1; C: Control; T + S: 10 ng/mL TGF-β1 and 12 mg/mL SBS.
S: 12 mg/mL SBS; *P < 0.01 vs. T; #P < 0.05 vs.T.
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with p-GSK-3β. The result is consistent with the obser-
vation that increased repression of GSK-3β after TGF-β
treatment [20].
TGF-β is potent inducer of epithelial-mesenchymal tran-
sition (EMT) in cell culture, especially in cancer-associated
EMT [21]. It is a key process for invasion and metastasis of
solid tumors [22]. There was well-documented evidence
supporting the notion that development of EMT in colo-
rectal cancer leads to an aggressive phenotype that may
promote metastatic spread and augment treatment resist-
ance [23]. Consistent with the previous reports [24,25], E-
cadherin level was downregulated, Snail, Vimentin and
Fibronectin were upregulated in our results. SBS lowers
the level of Wnt5a and reduces the markers of EMT.
Wnt5a is an effector of TGF-β in breast cancer [26].
TGF-β was found to upregulate Wnt5a expression
through direct formation of Smad complex or indirect
activation of NF-κB [27]. Wnt5a treatment activated
Snail and initiated the transition events [28,29]. So, it
promoted EMT with downregulation of E-cad and up-
regulation of Vimentin [30]. The upregulated Wnt5a by
TGF-β could be suppressed by SBS, suggested that SBS
might inhibit EMT process through downregulating
TGF-β [31].
EMT is an important cause for immune escape, in-
cluding CRC [32]. Tumor stroma components are en-
gaged in active molecular crosstalk that has serious
implications for immunological recognition of tumor in
shaping the microenvironment. Among stromal cells in-
filtrating tumors, MDSCs represented one of the most
important players mediating immunosuppression [33].
Tumor-derived factors support MDSCs generation, ex-
pansion and function. Consequently, MDSCs release
TGF-β and IL-10 facilitating the formation of an im-
munosuppressive environment. SBS reduced the number
of MDSCs and inhibited the generation of TGF-β1 inthe late stage of our experiment. MDSCs may participate
in the producing of TGF-β which inhibits cytotoxic
lymphocyte functions [13]. Together, SBS might reduce
the production of TGF-β by MDSCs to ameliorate
mesenchymal transition induced by AOM/DSS .
Advanced age, immunosuppressive cytokines from
chronic inflammation, tumor-derived immunosuppressive
factors and surrendered immune cells, such as MDSCs
constitute CRC microenvironment [34,35]. In TCM, the
key pathogenesis of CRC immunosuppressive microenvir-
onment is “Spleen-deficiency” [36]. SBS ameliorates im-
munosuppressive microenvironment through invigorating
Spleen and replenishing Qi, suggesting that the ancient
TCM theory “invigorating Spleen” is effective in prevent-
ing caCRC. Panax ginseng Ginsenoside and polysacchar-
ide prevented breast cancer metastasis and decreased
gastric cancer cell migration and invasion through redu-
cing the expression of EMT markers [37,38]. Korean red
ginseng enhanced T cell function by inhibiting the im-
munosuppressive activity of MDSCs [39]. These evi-
dences further support the efficacy of “invigorating
Spleen” herbs in the prevention of cancers through
regulating EMT and MDSCs.Conclusion
To conclude, AOM/DSS induce caCRC through upreg-
ulation of TGF-β1, which in turn activates Wnt5a and
subsequent EMT. caCRC recruits MDSCs to generate an
immunosuppressive microenvironment through TGF-β1.
SBS decreases TGF-β1 mediated EMT and β-catenin acti-
vation to alleviate carcinogenesis. It also decreases MDSCs
infiltration to ameliorate the immunosuppressive tumor
microenvironment [40]. Further studies will be con-
ducted to investigate how SBS regulates MDSCs and
its underlying mechanism in preventing CRC growth
and metastasis.
Additional files
Additional file 1:Figure S1. Similarity analyses of chromatographic SBS
samples. The Similarity Evaluation System for Chromatographic Fingerprint of
TCM (2004 A edition) was used to evaluate the similarities of the 7 batches
of SBS. After peak-picking, template-matching process, the peaks in the
spectra were matched automatically. Table S1. Comparability result of
reproducibility of SBS samples. The reference template was set finally
for spectra peak difference and entire similarity evaluation. The similarities of
repeatability were from 0.814 to 0.987. The results showed that the preparation
process of SBS was reasonable. Figure S2. The four matched references in
SBS sample. Determination of atractylenolide-1, atractylenolide −2, gensenoside
Rb1 and Rc in SBS sample: as the four active compounds in Atractylodes
macrocephala and Panax ginseng respectively, the determination of the four
compounds by the same HPLC eluted system could cotroll the quality of SBS.
Additional file 2: SBS (3.64 g/kg) was administered by gavage in
SBS-L group, SBS (7.28 g/kg) in SBS-M group, and SBS (14.56 g/kg)
in SBS-H group. (A) Microscopic view of neoplasma in mice. SBS reduced
the size of neoplasma in a dose-dependent manner. (B) Dose-depedent effects
of SBS on MDSCs and serum TGF-β1.SBS decreased the number of MDSCs
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*P < 0.01 vs. model, #P < 0.05 vs. model; △P < 0.01 vs. control, ▲P < 0.0 5 vs.
control.
Abbreviations
SBS: Shenling Baizhu San; CRC: Colorectal cancer; AOM: Azoxymethane;
DSS: Dextran sodium sulfate; caCRC: Colitis associated CRC; TGF-β1: Transforming
growth factor β1; ELISA: Enzyme-linked immunosorbent assay;
EMT: Epithelial mesenchymal transition; N-cad: N-cadherin; E-cad: E-cadherin;
MDSCs: Myeloid-derived suppressive cells; TCM: Traditional Chinese medicine;
Dvl2: Dishevelled-2; GSK-3β: Glycogen synthase kinase 3β.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XS and CL designed the study. XL, LJ and MS carried out experiments. WX
and GW performed statistical analysis. LZ, QF participated in the design of
study, interpretation of results. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by National Science Foundation of China (No.
81273621), Specialized Research Fund for the Doctoral Program of Higher
Education (No. 20134433110007) and Baiyun District Science and Technology
Program (No. 2012-KZ-81).
The authors thank Pro. Y.Y. Chen (School of Traditional Chinese Medicine,
Southern Medical University) for skillful technical assistance. We also thank
Dr. John Chu Man Tak (School of Chinese Medicine, Hong Kong Baptist
University) for language editing of the manuscript.
Author details
1Department of Traditional Chinese Medicine, Nanfang Hospital, Southern
Medical University, Guangzhou 510515, China. 2The Key Laboratory of
Molecular Biology, State Administration of Traditional Chinese Medicine;
School of Traditional Chinese Medicine, Southern Medical University,
Guangzhou 510515, China. 3Department of Imaging Center, Nanfang
hospital, Southern Medical University, Guangzhou 510515, China.
4Department of Anesthesiology, Yue Bei People’s Hospital, Shaoguan,
Guangdong Province, China. 5Traditional Chinese Medicine Integrated
Hospital, Southern Medical University, Guangzhou 510315Guangdong, China.
Received: 29 June 2014 Accepted: 15 April 2015
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.
2010;127(12):2893–917.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin.
2013;63(1):11–30.
3. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al.
Prognostic factors in colorectal cancer. College of American pathologists
consensus statement. Arch Pathol Lab Med 2000. 1999;124(7):979–94.
4. Lu KQ. [The applicatiion of Shenling Baizhu Power on postoperational
colorectal cancer]. Chin J Med. 2000;35(6):51.
5. Li PX, Jia YJ, Jia YT, Chen J. The observation of Shenling Baizhu San in
improving Pi-deficiency postoperation. J Tianjin Coll Tradit Chin Med.
2005;24(3):151–2.
6. Huang ZR, Wang Y, Wang RP, Chen JJ. Effects of Shenling Baizhu San on
serum IL-2, INF-γTNF-α in tumor bearing mice. Guangming J Chin Med.
2010;25(9):1584–6.
7. Li Z. [Changes of cellular immune function in Lewis mice with lung cancer
after Shenlingbaizhusan decoction treatment]. J Hainan Med Coll.
2013;19(6):738–42. 745.
8. Tang B. [Clinical observation of Shenling Baizhu San on 60 cases of chronic
enteritis]. Intern Med China. 2011;6(3):225–6.
9. Li XM. [Clinical observation of the efficacy of Shenling Baizhu powder on
treatment of chronic enteritis]. China Mod Med. 2012;19(15):90–1.10. Garrett WS, Punit S, Gallini CA, Michaud M, Zhang D, Sigrist KS, et al.
Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic
cells. Cancer Cell. 2009;16(3):208–19.
11. Zhu QC, Gao RY, Wu W, Qin HL. Epithelial-mesenchymal transition and its
role in the pathogenesis of colorectal cancer. Asian Pac J Cancer Prev.
2013;14(5):2689–98.
12. Kawakami Y, Yaguchi T, Sumimoto H, Kudo-Saito C, Iwata-Kajihara T, Nakamura
S, et al. Improvement of cancer immunotherapy by combining molecular
targeted therapy. Front Oncol. 2013;3:136.
13. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s
roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.
14. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, et al. Mesenchymal
transition and dissemination of cancer cells is driven by myeloid-derived
suppressor cells infiltrating the primary tumor. PLoS Biol.
2011;9(9):e1001162.
15. Li H, Wu WK, Li ZJ, Chan KM, Wong CC, Ye CG, et al. 2,3′,4,4′,5′-
Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-
associated colorectal carcinogenesis in mice. Br J Pharmacol.
2010;160(6):1352–61.
16. Lin X, Yi Z, Diao J, Shao M, Zhao L, Cai H, et al. ShaoYao decoction ameliorates
colitis-associated colorectal cancer by downregulating proinflammatory cytokines
and promoting epithelial-mesenchymal transition. J Transl Med. 2014;12(1):105.
17. Attisano L, Wrana JL. Signal integration in TGF-beta, WNT, and Hippo pathways.
F1000Prime Rep. 2013;5:17.
18. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links
inflammation and tumorigenesis in a mouse model of colitis-associated
cancer. Cell. 2004;118(3):285–96.
19. Yazlovitskaya EM, DeHaan RD, Persons DL. Prolonged wild-type p53 protein
accumulation and cisplatin resistance. Biochem Biophys Res Commun.
2001;283(4):732–7.
20. Amini NS, Ebrahim RP, Van Dam K, Cassiman JJ, Tejpar S. TGF-beta modulates
beta-Catenin stability and signaling in mesenchymal proliferations. Exp Cell Res.
2007;313(13):2887–95.
21. Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in
TGF-beta-induced epithelial-mesenchymal transition. Curr Opin Cell Biol.
2014;31C:56–66.
22. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions
in development and disease. Cell. 2009;139(5):871–90.
23. Bhangu A, Wood G, Mirnezami A, Darzi A, Tekkis P, Goldin R. Epithelial
mesenchymal transition in colorectal cancer: Seminal role in promoting
disease progression and resistance to neoadjuvant therapy. Surg Oncol.
2012;21(4):316–23.
24. Wang H, Wang HS, Zhou BH, Li CL, Zhang F, Wang XF, et al. Epithelial-mesenchymal
transition (EMT) induced by TNF-alpha requires AKT/GSK-3beta-mediated
stabilization of snail in colorectal cancer. PLoS One. 2013;8(2):e56664.
25. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, et al.
Loss of p53 in enterocytes generates an inflammatory microenvironment
enabling invasion and lymph node metastasis of carcinogen-induced colorectal
tumors. Cancer Cell. 2013;23(1):93–106.
26. Serra R, Easter SL, Jiang W, Baxley SE. Wnt5a as an effector of TGFbeta in
mammary development and cancer. J Mammary Gland Biol Neoplasia.
2011;16(2):157–67.
27. Katoh M, Katoh M. Transcriptional mechanisms of WNT5A based on NF-kappaB,
Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med.
2009;23(6):763–9.
28. Dissanayake SK, Wade M, Johnson CE, O’Connell MP, Leotlela PD, French AD,
et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma
cells via the inhibition of metastasis suppressors and initiation of an epithelial
to mesenchymal transition. J Biol Chem. 2007;282(23):17259–71.
29. Sipos F, Galamb O. Epithelial-to-mesenchymal and mesenchymal-to-epithelial
transitions in the colon. World J Gastroenterol. 2012;18(7):601–8.
30. Bo H, Zhang S, Gao L, Chen Y, Zhang J, Chang X, et al. Upregulation of
Wnt5a promotes epithelial-to-mesenchymal transition and metastasis of
pancreatic cancer cells. BMC Cancer. 2013;13(1):496.
31. Thakur N, Gudey SK, Marcusson A, Fu JY, Bergh A, Heldin CH, et al.
TGFbeta-induced invasion of prostate cancer cells is promoted by
c-Jun-dependent transcriptional activation of Snail1. Cell Cycle.
2014;13(15):2400–14.
32. Fu Y, Liu X, Zhou N, Du L, Sun Y, Zhang X, et al. MicroRNA-200b stimulates
tumour growth in TGFBR2-null colorectal cancers by negatively regulating
p27/kip1. J Cell Physiol. 2013;229(6):772–82.
Lin et al. BMC Complementary and Alternative Medicine  (2015) 15:126 Page 15 of 1533. Sevko A, Umansky V. Myeloid-derived suppressor cells interact with tumors
in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as
thieves. J Cancer Educ. 2013;4(1):3–11.
34. Beauchemin N. The colorectal tumor microenvironment: the next decade.
Cancer Microenviron. 2011;4(2):181–5.
35. Kanterman J, Sade-Feldman M, Baniyash M. New insights into chronic
inflammation-induced immunosuppression. Semin Cancer Biol.
2012;22(4):307–18.
36. Chen Z, Chen LY, Wang P, Dai HY, Gao S, Wang K. Tumor
microenvironment varies under different TCM ZHENG models and
correlates with treatment response to herbal medicine. Evid Based
Complement Alternat Med. 2012;2012:635702.
37. Wang W, Zhang X, Qin JJ, Voruganti S, Nag SA, Wang MH, et al. Natural
product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and
metastasis through down-regulating MDM2. PLoS One. 2012;7(7):e41586.
38. Cai JP, Wu YJ, Li C, Feng MY, Shi QT, Li R, et al. Panax ginseng
polysaccharide suppresses metastasis via modulating Twist expression in
gastric cancer. Int J Biol Macromol. 2013;57:22–5.
39. Jeon C, Kang S, Park S, Lim K, Hwang KW, Min H. T cell stimulatory effects of
Korean Red ginseng through modulation of myeloid-derived suppressor cells.
J Ginseng Res. 2011;35(4):462–70.
40. Bissell MJ, Hines WC. Why don’t we get more cancer? a proposed role of
the microenvironment in restraining cancer progression. Nat Med.
2011;17(3):320–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
